

Cover Story
FreeNews Analysis
By Matthew Bin Han Ong
Now that Joseph R. Biden Jr. is inaugurated and safely ensconced in the White House, cancer groups expect him to pick up where he left off as vice president four years ago—pursuing a sober and ambitious agenda for accelerating progress in cancer research.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- How will FDA regulate psychedelics?
- The future of oncology: Early-career scientists need mentorship and a new academic model
- The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long” - OMB proposal to sideline peer review sparks widespread opposition
Nearly 500,000 public comments flood in—here are some highlights - Mail-out colorectal cancer screening programs extend, rather than replace, clinical care














